Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc.
H.C. Wainwright’s Mitchell Kapoor maintained Halozyme Therapeutics Inc. (NASDAQ:HALO) at a $72 price target and a Buy rating on May 29. The analyst expressed ongoing confidence in the company ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme ...
H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $68 from $65 and keeps a Buy rating on the shares post the Q3 report. The company reported a “substantial” sales beat, driven by a ...
Halo fans hoping to hop right into Halo: Combat Evolved Anniversary multiplayer when The Master Chief Collection launches tonight at midnight are out of luck. Developer 343 Industries has announced ...
The halting, years-long effort to turn Microsoft’s $2 billion Halo video-game franchise into a movie is again moving forward: Insiders tell Vulture that DreamWorks Pictures is renewing its efforts to ...
If you’re anything like the Halo fans here at XboxEra, you’ve probably always wondered what happens to Master Chief and The Weapon post rolling credits on Halo Infinite. Well, wonder no more, as a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback